ABT logo

ABBOTT LABORATORIES

ABTNYSE
πŸ† #84 by market capEarnings Oct 21US Equity
$99.73β–Ό $1.24 (βˆ’1.24%)
Live
πŸ””
Track ABT
Get earnings, price moves & breaking news on Telegram
Track
24hβ–Ό 1.2%
7dβ–Ό 3.9%
14dβ–Ό 2.3%
30dβ–Ό 11.3%
ytdβ–Ό 20.4%
1yβ–Ό 25.1%
🏦Market Cap
$172.57B
Mid Cap
πŸ“ˆRevenue Growth (YoY)
+5.7%
Slowing
πŸ“ŠGross Margin
56.8%
Healthy
πŸ’΅FCF Margin
18.7%
Healthy
βš–οΈP/S Ratio
3.8x
Fair
Otter Score
64
Fair

Trading Snapshot

Day Range
$98.66 – $101.22
52-Week Range
$81.97 – $135.45
Volume
$8.84B
Avg Volume
$6.30B
Shares Outstanding
1.73B
Next Earnings
Nov 3, 2026

Fundamentals Snapshot

Annual Revenue
$44.33B
Last Q Revenue
$12.59B
P/E Ratio
32.6
P/S Ratio
3.8x
EPS (TTM)
$3.11
Dividend Yield
2.45%
Dilution (1yr)
+0.1%

Why Investors Own ABT

  • βœ“High-growth profile β€” revenue up +1.5% YoY with expanding US Equity exposure.
  • βœ“Healthy economics β€” 67% gross margin and 19% free-cash-flow margin.
  • βœ“New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

ABT logo

ABBOTT LABORATORIES

ABT
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$44.3Bβ–² +5.7% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
55.5%β–² +9.2% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
$8.0Bβ–² +17.9% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
$7.4Bβ–² +16.4% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
1.75Bβ–² +0.1% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
βˆ’$6.5Bβ–² +$1.1B YoY
StockOtter Β· stockotter.space

About ABBOTT LABORATORIES

Abbott Laboratories, along with its affiliated entities, is a global healthcare enterprise dedicated to the research, development, manufacturing, and worldwide distribution of a diverse portfolio of health solutions. The company operates through four primary divisions: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. In the Established Pharmaceutical Products segment, Abbott provides generic medications designed to treat a wide array of conditions, including pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorders, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine. This segment also supplies the anti-infective clarithromycin, influenza vaccines, and products aimed at regulating colon physiology. The Diagnostic Products division offers a comprehensive suite of diagnostic tools. These include laboratory systems for immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and quantify infectious agents. Additionally, this segment provides point-of-care systems, blood testing cartridges, rapid lateral flow testing products, and specialized molecular point-of-care tests for pathogens such as HIV, SARS-CoV-2, influenza A and B, RSV, and strep A. Its offerings also extend to cardiometabolic test systems, drug and alcohol screening solutions, remote patient monitoring, consumer self-test systems, and sophisticated informatics and automation solutions for laboratory use. The Nutritional Products segment is responsible for delivering nutritional formulations tailored for both pediatric and adult populations. Finally, the Medical Devices segment develops and commercializes rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular ailments. It also supplies diabetes care products and neuromodulation devices designed for the management of chronic pain and movement disorders. Founded in 1888, Abbott Laboratories maintains its corporate headquarters in North Chicago, Illinois.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)
πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
⚑Momentumβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Fair
64/100

Analyst Price Target

β“˜
Average Target
$129.85
β–² +30.2% Upside
High Target$154.73
Low Target$118.33
Based on 37 analysts

Latest News & Updates

24/7 Wall StreetΒ·7h ago

3 Historically Stable Dividend Raisers in Medical Devices Offering Solid Yields With Fortress-Like Growth

Pacemakers and glucose monitors keep selling whether the economy booms or collapses, and three medical device giants have spent decades turning that predictable demand into paychecks that grow every single year.

Seeking AlphaΒ·3d ago

Best Dividend Kings: September 2026

Dividend Kings are underperforming SPY in September, with a -4.22% average return versus SPY's marginal gain. Despite aggregate weakness, 29 Dividend Kings appear both undervalued and offer a long-term expected return of

Zacks Investment ResearchΒ·4d ago

NVST vs. ABT: Which Stock Is the Better Value Option?

Investors with an interest in Medical - Products stocks have likely encountered both Envista (NVST) and Abbott (ABT). But which of these two companies is the best option for those looking for undervalued stocks?

Zacks Investment ResearchΒ·4d ago

Abbott (ABT) Registers a Bigger Fall Than the Market: Important Facts to Note

Abbott (ABT) concluded the recent trading session at $101.07, signifying a -2.34% move from its prior day's close.

Defense WorldΒ·5d ago

Envestnet Asset Management Inc. Sells 1,228,773 Shares of Abbott Laboratories $ABT

Envestnet Asset Management Inc. trimmed its position in shares of Abbott Laboratories (NYSE: ABT) by 23.7% in the undefined quarter, according to the company in its most recent Form 13F filing with the Securities and Exc

Defense WorldΒ·5d ago

Abbott Laboratories $ABT Shares Sold by Engineers Gate Manager LP

Engineers Gate Manager LP reduced its position in Abbott Laboratories (NYSE: ABT) by 97.1% in the undefined quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutiona